U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018245) titled 'Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder' on June 04.
Brief Summary: This study is a phase II, randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical trial and 150 subjects with depressive disorder will be enrolled. Subjects will be randomly assigned in a 1:1 ratio to two cohorts (Cohort 1: 200 mg dose group; Cohort 2: 400 mg dose group). Within each cohort, subjects will be randomized in a 2:1 ratio to either the TJ0113 capsule group or the placebo group, with approximately 50 subjects receiving TJ0113 capsules and approximately 25 receiving placebo. Approx...